Colin Richard Dorgan

This inventor holds 10 USPTO granted patents and 9 published patent applications, plus 4 CIPO patents and 6 EPO patents. Top assignees: Summit Corporation Plc, Oxagen Limited, Summit Therapeutics Plc. Active years: 2011-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Colin Richard Dorgan. Retrieved from https://idiyas.com/inventor/colin-richard-dorgan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 9)

% Patents Active = 40.0

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 6.5

ph-index = 5

Forward Citations = 97(Granted Patents)

Location History:

Oxon, GB (2012)
Oxford, GB (2013)
Abingdon Oxfordshire, GB (2015)
Oxfordshire, GB (2015)
Abingdon, GB (2011 - 2017)

Company Filing History:

4 out of 6

Summit Corporation Plc

Summit Therapeutics Plc

patents

Years Active: 2011-2017

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9763925 - Antibacterial compounds (2017-09-19),

2. 9314456 - Antibacterial compounds (2016-04-19),

3. 9278091 - [object Object] (2016-03-08),

4. 8987308 - [object Object] (2015-03-24),

5. 8975416 - Antibacterial compounds (2015-03-10),

6. 8518980 - Treatment of Duchenne muscular dystrophy (2013-08-27),

7. 8501713 - Drug combinations for the treatment of duchenne muscular dystrophy (2013-08-06),

8. 8268878 - Compounds having CRTH2 antagonist activity (2012-09-18),

9. 8168673 - Compounds having CRTH2 antagonist activity (2012-05-01),

10. 7999119 - Compounds having CRTH2 antagonist activity (2011-08-16),

Title: Colin Richard Dorgan: Innovator in Antibacterial Compounds

Introduction

Colin Richard Dorgan is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of antibacterial compounds, holding a total of 10 patents. His work focuses on developing innovative solutions for treating bacterial diseases and infections.

Latest Patents

Dorgan's latest patents include compounds of formula (I), which are designed for the treatment of bacterial diseases and infections. These compounds are integral to compositions that aid in combating infections caused by various bacterial strains. The methods he has developed for treating these diseases highlight the importance of his research in the medical field.

Career Highlights

Throughout his career, Colin Richard Dorgan has worked with prominent companies such as Summit Corporation Plc and Oxagen Limited. His experience in these organizations has allowed him to refine his expertise in the development of antibacterial solutions.

Collaborations

Some of his notable coworkers include Peter David Johnson and Graham Michael Wynne. Their collaboration has contributed to the advancement of research in antibacterial compounds.

Conclusion

Colin Richard Dorgan's innovative work in antibacterial compounds has made a significant impact on the treatment of bacterial infections. His patents and collaborations reflect his dedication to advancing medical science.

Profile summary based on public USPTO records.